This specialized webinar provides legal professionals with an objective, evidence-based pharmacological framework for handling complex impairment questions in DUI, assault, custody, and homicide cases. Designed to separate medical reality from pervasive courtroom misconceptions, the presentation equips attorneys to distinguish the mere presence of a drug from actual clinical impairment using objective clinical signs. Participants will explore how physiological tolerance alters medication effects, learning why a chronic, stable user can maintain normal cognition and drive safely on a dose that would severely incapacitate an opioid-naive individual. The curriculum deconstructs common prosecution overstatements regarding polypharmacy, clarifies the clinical realities of opioid-alcohol co-ingestion, and debunks myths regarding drug withdrawal. Furthermore, the session demystifies psychiatric drug classes, explaining why medications like “antipsychotics” are routinely prescribed for non-psychotic conditions such as insomnia or depression, which can otherwise unfairly prejudice a jury. Finally, attendees will learn how to systematically review prescription histories, recognize the steep limitations of toxicology screens, and structure strategic cross-examinations of Drug Recognition Expert (DRE) testimony to challenge subjective assumptions with patient-specific data.

Highlights (5-10 mins, each section) 

  • Presence Does Not Equal Impairment 
  • The Power of Physiological Tolerance 
  • Mislabeled Drug Classes Prejudice Juries
  • Urine Testing is Useless for Acute Impairment 
  • Debunking the “Withdrawal Rage” Myth 
  • Polypharmacy is Often Safe and Stable 

Objectives 

Upon completion of this course, the attendee will:  

  1. Distinguish between acute drug use and chronic stable therapy by analyzing how physiological tolerance mitigates the sedating and cognitive effects of opioids and benzodiazepines.
  2. Evaluate toxicology report data to determine whether positive results confirm active clinical impairment or merely indicate historical exposure within the substance’s detection window.
  3. Identify and counter categorical overstatements regarding polypharmacy, withdrawal, and drug combinations by demanding patient-specific, objective clinical findings.
  4. Contextualize psychiatric medication classes (such as atypical antipsychotics) using prescriber notes to prevent misleading drug nomenclature from prejudicing a jury.
  5. Formulate targeted cross-examination strategies for opposing experts and Drug Recognition Experts (DRE) by systematically reviewing refill histories, dosage stability, and documented scene observations